A Study to investigate the role of p27 and Cyclin E immunoexpression as a prognostic factor in early breast carcinoma

World Journal of Surgical Oncology

Volumn 9, Issue , 2011, Pages

  Pillay, Komala ^a   McCleod, Heather ^a   Chetty, Runjan ^b   Hall, Pauline ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; ESTROGEN RECEPTOR; PROTEIN P27; CYCLIN DEPENDENT KINASE INHIBITOR 1B;

ARTICLE; BREAST CARCINOMA; CANCER INVASION; CONTROLLED STUDY; DISTANT METASTASIS; EARLY CANCER; EXCISION; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; SURVIVAL TIME; TUMOR VOLUME; ADULT; AGED; BREAST TUMOR; CHEMISTRY; FEMALE; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS;

EID: 79952700986     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-9-31     Document Type: Article

References (32)

1. Chetty R. Cyclin E and p27/Kip1: two proteins on a see-saw or another false dawn?. Histopathology 2002, 40(4):393-394. 10.1046/j.1365-2559.2002.01299.x, 11943027.
2. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995, 11(2):211-219.
3. Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999, 50:401-423. 10.1146/annurev.med.50.1.401, 10073286.
4. Ohtsubo M, Theodoras AM, Schumacher J. Human cyclin E, a nuclear protein essential for the G1 to S transition. Mol Cell Biol 1995, 5:2612-2624.
5. Soos TJ, Kiyokawa H, Yan JS. Formation of p27-CDK complexes during the human mitotic cycle. Cell Growth Differ 1996, 7:135-146.
6. Gong J, Traganos F, Darzynkiewicz Z. Threshold expression of cyclin E but not D type cyclins characterizes normal and tumour cells entering S phase. Cell Prolif 1995, 28(6):337-346. 10.1111/j.1365-2184.1995.tb00075.x, 7626688.
7. Huang M, Yang S, Liao S, Zhang B, You J. [The effects of cyclin E on the growth and other cell cycle related genes of breast carcinoma cells MCF-7]. Zhonghua Bing Li Xue Za Zhi 2000, 29(3):192-195.
8. Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications. Hum Pathol 2001, 32(1):89-94. 10.1053/hupa.2001.21141, 11172300.
9. Sasano H, Frost AR, Saitoh R, Taniyama Y, Nagura H, Matsunaga G, Takehana K, Kimura M, Silverberg SG. Immunolocalization of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human breast carcinoma. Anticancer Res 1997, 17(5A):3685-3690.
10. Kim HK, Park IA, Heo DS, Noh DY, Choe KJ, Bang YJ, Kim NK. Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer. Eur J Surg Oncol 2001, 27(5):464-471. 10.1053/ejso.2001.1137, 11504517.
11. Gillett CE, Smith P, Peters G, Lu X, Barnes DM. Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma. J Pathol 1999, 187(2):200-206. 10.1002/(SICI)1096-9896(199901)187:2<200::AID-PATH228>3.0.CO;2-M, 10365095.
12. Reed W, Florems VA, Holm R, Hannisdal E, Nesland JM. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Virchows Arch 1999, 435(2):116-124. 10.1007/s004280050408, 10599310.
13. Chetty R. Cyclin E and p27: Their putative role as prognostic markers. Curr Diag Pathol 2002, 8(5):289-296.
14. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol 2005, 16(11):1723-1739. 10.1093/annonc/mdi352, 15980158.
15. Caldon CE, Daly RJ, Sutherland RL, Musgrove EA. Cell cycle control in breast cancer cells. J Cell Biochem 2005,
16. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002, 8(10):1145-1152. 10.1038/nm759, 12244301.
17. Said TK, Moraes RC, Singh U, Kittrell FS, Medina D. Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia. Cell Growth Differ 2001, 12(6):285-295.
18. Rasmussen UB, Wolf C, Mattei MG, Chenard MP, Bellocq JP, Chambon P, Rio MC, Basset P. Identification of a new interferon-alpha-inducible gene (p27) on human chromosome 14q32 and its expression in breast carcinoma. Cancer Res 1993, 53(17):4096-4101.
19. Tigli H, Buyru N, Dalay N. Molecular analysis of the p27/kip1 gene in breast cancer. Mol Diagn 2005, 9(1):17-21. 10.2165/00066982-200509010-00003, 16035731.
20. Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP. p27/Kip1 mutation found in breast cancer. Cancer Res 1996, 56(10):2400-2404.
21. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997, 57(7):1259-1263.
22. Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res 1999, 59(3):684-688.
23. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997, 3(2):222-225. 10.1038/nm0297-222, 9018243.
24. Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, et al. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V. Cancer 2003, 97(7):1591-1600. 10.1002/cncr.11224, 12655514.
25. Barbareschi M, van Tinteren H, Mauri FA, Veronese S, Peterse H, Maisonneuve P, Caffo O, Scaioli M, Doglioni C, Galligioni E, et al. p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer 2000, 89(3):236-241. 10.1002/1097-0215(20000520)89:3<236::AID-IJC5>3.0.CO;2-Z, 10861499.
26. Barbareschi M. p27 Expression, a cyclin dependent kinase inhibitor in breast carcinoma. Adv Clin Path 1999, 3(4):119-127.
27. Blegen H, Ghadimi BM, Jauho A, Zetterberg A, Eriksson E, Auer G, Ried T. Genetic instability promotes the acquisition of chromosomal imbalances in T1b and T1c breast adenocarcinomas. Anal Cell Pathol 2001, 22(3):123-131.
28. Keyomarsi K, Tucker SL, Buchholz TA. Cyclin E and survival in patients with breast cancer. N Eng J Med 2002, 347:1566-1575.
29. Porter PL, Lund MJ, Lin MG, Yuan X, Liff JM, Flagg EW, Coates RJ, Eley JW. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 2004, 100(12):2533-2542. 10.1002/cncr.20279, 15197793.
30. Joe AK, Memeo L, McKoy J, Mansukhani M, Liu H, Avila-Bront A, Romero J, Li H, Troxel A, Hibshoosh H. Cyclin D1 overexpression is associated with estrogen receptor expression in Caucasian but not African-American breast cancer. Anticancer Res 2005, 25(1A):273-281.
31. Coradini D, Pellizzaro C, Veneroni S, Ventura L, Daidone MG. Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer 2002, 87(10):1105-1111. 10.1038/sj.bjc.6600556, 2376202, 12402149.
32. Orlando L, Renne G, Rocca A, Curigliano G, Colleoni M, Severi G, Peruzzotti G, Cinieri S, Viale G, Sanna G, et al. Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. Ann Oncol 2005, 16(7):1094-1099. 10.1093/annonc/mdi213, 15855225.